Abstract
Edaravone is a free radical scavenger with brain protection properties and is recommended by "The Japanese Guidelines for the Management of Stroke 2009" for administration to adult patients, in whom it has been shown to improve neurological deficits after cerebral infarction. However, its dosage and effects have not yet been established in children. Seventeen pediatric patients with cerebral ischemia were administered edaravone at a dose based on body weight from the standard dose given to adults. Functional outcomes were evaluated using mRS and PSOM (modified ranking scale and pediatric stroke outcome scale, respectively). Immediate post-treatment results were mostly positive, with no liver or renal complications. In some cases, neurological symptoms markedly improved after the administration of edaravone. The efficacy of edaravone has not yet been examined in pediatric patients. The results of the present study suggest that edaravone has potential in the treatment of children safely with promising results similar to those in adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
